News archive
Showing 644 results
November 2018
-
Media ReleaseFDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
-
Media ReleaseNovartis to fund five innovative ideas to support patients and the sickle cell community- 2018 STEP Program™ designed to support unique proposals from nonprofit organizations that serve people living with sickle cell disease- Novartis will select proposals that demonstrate innovation in…
-
Media ReleaseNovartis to fund five innovative ideas to support patients and the sickle cell community
-
Media ReleaseNew Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patientsEntresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker…
-
Media ReleaseNew Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
-
Media ReleaseNovartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology- Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2…
-
Media ReleaseNovartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
October 2018
-
Media ReleaseNovartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®-- Kymriah was the first CAR-T cell therapy to ever be approved by a regulatory authority-- Since 1970, more than 40 Novartis innovative therapies have been recognized by the Prix Galien Foundation…
-
Media ReleaseNovartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®
-
Media ReleaseTwo-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD- Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept- Superior reductions in central…
-
Media ReleaseTwo-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
-
Media ReleaseNovartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitisNew data show that 73% of ankylosing spondylitis (AS) patients taking Cosentyx® (secukinumab) achieved improvement in AS signs and symptoms at four years, with sustained ASAS response rates1 AS is a…